# Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

> **NCT00233558** · PHASE4 · TERMINATED · sponsor: **Abbott** · enrollment: 160 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** adalimumab (up to 9 months exposure)
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00233558
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 160 (—)
- **Why stopped:** Study terminated due to low subject enrollment. Safety results consistent with product label.
- **Last updated:** 2007-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233558, "Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00233558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*